Published in J Infect Dis on October 01, 1969
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother (1986) 3.38
Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother (1978) 2.79
Amphotericin B serum concentrations during therapy. Appl Microbiol (1970) 2.66
Pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother (1972) 2.14
Laboratory tests of antifungal drugs. J Clin Pathol (1975) 2.14
Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob Agents Chemother (1985) 1.78
Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob Agents Chemother (1986) 1.77
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother (2001) 1.51
Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother (1989) 1.48
Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother (2003) 1.44
Effect of rapid intravenous infusion on serum concentrations of amphotericin B. Appl Microbiol (1971) 1.43
Cryptococcosis after renal transplantation: report of ten cases. Surgery (1976) 1.41
Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother (1991) 1.39
Amphotericin B therapy in an anephric patient. Antimicrob Agents Chemother (1973) 1.38
In vitro susceptibility of isolates of Aspergillus fumigatus and Sporothrix schenckii to amphotericin B. Antimicrob Agents Chemother (1972) 1.37
Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother (1985) 1.34
Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine. Antimicrob Agents Chemother (1977) 1.32
Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (1984) 1.31
Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother (2005) 1.23
Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother (1994) 1.23
Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother (2006) 1.19
Comparative pharmacology of amphotericin B and amphotericin B methyl ester in the non-human primate, Macacca mulatta. Antimicrob Agents Chemother (1977) 1.15
Stability of amphotericin B in infusion bottles. Antimicrob Agents Chemother (1973) 1.11
Effect of amphotericin B and clotrimazole on lymphocyte stimulation. Antimicrob Agents Chemother (1974) 1.11
Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ (1992) 1.10
Candida infections in surgical patients. Dose requirements and toxicity of amphotericin B. Ann Surg (1982) 1.09
Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob Agents Chemother (1985) 1.07
Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory. J Clin Microbiol (1995) 1.05
Simple assay for 5-fluorocytosine in the presence of amphotericin B. Antimicrob Agents Chemother (1976) 1.05
Neutrophil toxicity of amphotericin B. Antimicrob Agents Chemother (1977) 1.04
Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob Agents Chemother (1997) 1.01
Pharmacokinetics of amphotericin B and flucytosine. Postgrad Med J (1979) 0.96
Interaction of chemotherapy and immune defenses in experimental murine cryptococcosis. Antimicrob Agents Chemother (1978) 0.96
Systemic mycoses in dogs and cats. Can Vet J (1971) 0.94
Speciation and amphotericin B sensitivity studies on blood isolates of Candida from burned patients. J Clin Pathol (1973) 0.93
Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison. Bull World Health Organ (1994) 0.93
Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrob Agents Chemother (1998) 0.92
Rifampin: inhibition of ribonucleic acid synthesis after potentiation by amphotericin B in Saccharomyces cerevisiae. Antimicrob Agents Chemother (1974) 0.91
Pharmacokinetics of liposomal amphotericin B in pleural fluid. Antimicrob Agents Chemother (2010) 0.89
Combined activity of minocycline and amphotericin B in vitro against medically important yeasts. Antimicrob Agents Chemother (1978) 0.88
Effects of amphotericin B on hepatitis B virus. Antimicrob Agents Chemother (1981) 0.87
Management of pulmonary aspergilloma in the presence of active tuberculosis. Thorax (1984) 0.86
Chemotherapy of experimental endogenous Candida albicans endophthalmitis. Trans Am Ophthalmol Soc (1980) 0.84
5-fluorocytosine and amphotericin B in bronchial secretions. Antimicrob Agents Chemother (1974) 0.83
Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride. Am J Trop Med Hyg (2010) 0.83
Radiometric determination of the concentration of amphotericin B in body fluids. Antimicrob Agents Chemother (1977) 0.81
Amphotericin B and 5-fluorocytosine: in vitro effects on lymphocyte function. Antimicrob Agents Chemother (1978) 0.81
Utilization and comparative effectiveness of caspofungin and voriconazole early after market approval in the U.S. PLoS One (2014) 0.81
Cryptococcosis. A cause of calcified intracranial mass lesions. Calif Med (1973) 0.79
Toxicity of amphotericin B, miconazole, and ketoconazole to human granulocyte progenitor cells in vitro. Antimicrob Agents Chemother (1983) 0.79
Therapy of fungal infections of the central nervous system. Postgrad Med J (1979) 0.79
New automated method for determining postantifungal effect of amphotericin B against Candida species: effects of concentration, exposure time, and area under the curve. Antimicrob Agents Chemother (2002) 0.79
Measurement of the concentration of amphotericin B in brain tissue of scrapie-infected hamsters with a simple and sensitive method. Antimicrob Agents Chemother (1991) 0.78
Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells. Br J Cancer (1994) 0.77
Therapy of fungal infections. Bull N Y Acad Med (1982) 0.75
Systemic antifungal agents. Tex Heart Inst J (1990) 0.75
Pediatric antimicrobial therapy. VI. Can Med Assoc J (1973) 0.75
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol (1982) 6.78
Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med (1974) 6.75
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother (1973) 5.84
Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol (1984) 5.74
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med (1968) 4.97
Taxonomic studies on Filobasidiella species and their anamorphs. Antonie Van Leeuwenhoek (1982) 4.90
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis (1983) 4.42
Chronic mucocutaneous candidiasis: model-building in cellular immunity. Ann Intern Med (1971) 4.41
Chemotherapy of systemic mycoses (first of two parts). N Engl J Med (1974) 4.20
Epidemiologic differences among serotypes of Cryptococcus neoformans. Am J Epidemiol (1977) 3.91
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med (1996) 3.76
Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J Infect Dis (1972) 3.75
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Distribution of alpha and alpha mating types of Cryptococcus neoformans among natural and clinical isolates. Am J Epidemiol (1978) 3.55
Control for rheumatoid factor in the latex test for cryptococcosis. Am J Clin Pathol (1971) 3.47
The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol (1974) 3.38
Capsular polysaccharides of Cryptococcus neoformans. Rev Infect Dis (1984) 3.10
Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother (1978) 2.79
Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans. J Infect Dis (1973) 2.45
Growth of Cryptococcus neoformans within human macrophages in vitro. Infect Immun (1973) 2.39
Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother (1995) 2.32
Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med (1974) 2.25
Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis (1987) 2.18
Pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother (1972) 2.14
Detection of Candida antigen in sera of patients with candidiasis by an enzyme-linked immunosorbent assay-inhibition technique. J Clin Microbiol (1979) 2.13
Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis (1995) 2.11
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun (1991) 2.11
New, special stain for histopathological diagnosis of cryptococcosis. J Clin Microbiol (1981) 2.04
5-fluorocytosine resistance in Cryptococcus neoformans. Antimicrob Agents Chemother (1973) 2.00
Clotrimazole: new drug for systemic mycoses? Ann Intern Med (1970) 1.99
Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol (1975) 1.99
Invasive aspergillosis. Absence of detectable antibody response. Am Rev Respir Dis (1971) 1.96
Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol (1998) 1.83
Biochemical differences between serotypes of Cryptococcus neoformans. Sabouraudia (1978) 1.83
Complement depletion in cryptococcal sepsis. J Immunol (1978) 1.82
Serology of human cryptococcosis. Ann Intern Med (1968) 1.78
Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata. Antimicrob Agents Chemother (1998) 1.76
Chemotherapy of systemic mycoses (second of two parts). N Engl J Med (1974) 1.73
Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography. Antimicrob Agents Chemother (1991) 1.72
Selection of ura5 and ura3 mutants from the two varieties of Cryptococcus neoformans on 5-fluoroorotic acid medium. J Med Vet Mycol (1992) 1.71
High prevalence of Cryptococcus neoformans var. gattii in tropical and subtropical regions. Zentralbl Bakteriol Mikrobiol Hyg A (1984) 1.68
Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med (1974) 1.63
Experience with a new skin test antigen prepared from Cryptococcus neoformans. Am Rev Respir Dis (1968) 1.62
Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med (1973) 1.61
Diagnosis of systemic candidiasis by latex agglutination for serum antigen. J Clin Microbiol (1985) 1.56
Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis (1990) 1.55
Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis. J Clin Invest (1982) 1.53
Diversity of DNA fingerprints in Cryptococcus neoformans. J Clin Microbiol (1995) 1.50
Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) (1993) 1.50
The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis. Proc Soc Exp Biol Med (1973) 1.49
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Rapid diagnosis of candidiasis and aspergillosis. Rev Infect Dis (1987) 1.41
Mode of action of 5-fluorocytosine. Biochem Pharmacol (1978) 1.40
Flucytosine interference in creatinine assay. J Infect Dis (1990) 1.39
The passion and action of our time and surgical excellence. Am J Surg (1974) 1.39
Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother (1978) 1.38
The role of late complement components and the alternate complement pathway in experimental cryptococcosis. Proc Soc Exp Biol Med (1973) 1.38
Receptor-mediated clearance of Aspergillus galactomannan. J Infect Dis (1987) 1.35
Breast volume and anthropomorphic measurements: normal values. Plast Reconstr Surg (1986) 1.31
Cloning and characterization of a Candida albicans maltase gene involved in sucrose utilization. J Bacteriol (1992) 1.29
Searching for the yeast connection. N Engl J Med (1990) 1.29
Oxidative killing of Aspergillus fumigatus proceeds by parallel myeloperoxidase-dependent and -independent pathways. Infect Immun (1987) 1.26
Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis (2001) 1.26
Aspergillus infections in cancer patients. Association with fireproofing materials in a new hospital. JAMA (1976) 1.25
Chronic meningitis. Medicine (Baltimore) (1976) 1.25
Galactofuranosyl groups are immunodominant in Aspergillus fumigatus galactomannan. Mol Immunol (1985) 1.23
Lectin-like attachment sites on murine pulmonary alveolar macrophages bind Aspergillus fumigatus conidia. J Infect Dis (1988) 1.22
Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis (1991) 1.18
Pharmacokinetics of intrathecally administered amphotericin B. Am Rev Respir Dis (1969) 1.17
Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene (1999) 1.16
Efficacies of four antifungal agents in experimental murine sporotrichosis. Antimicrob Agents Chemother (1988) 1.16
Variant forms of pulmonary cryptococcosis. Ann Intern Med (1968) 1.15
A subcutaneous reservoir for intrathecal therapy of fungal meningitis. N Engl J Med (1973) 1.13
In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis (1991) 1.13
Chronic meningitis caused by Cladosporium trichoides. Am J Clin Pathol (1973) 1.12
Expanding forearm hematoma after apparent minor injury. Plast Reconstr Surg (1965) 1.12
Chronic fungal sinusitis in apparently normal hosts. Medicine (Baltimore) (1988) 1.12
Stability of amphotericin B in infusion bottles. Antimicrob Agents Chemother (1973) 1.11
Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob Agents Chemother (2000) 1.09
Clinical features of extracutaneous sporotrichosis. Medicine (Baltimore) (1967) 1.08
Differences in Cryptococcus neoformans capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces. Mol Immunol (1991) 1.06
Inhibition of complement by culture supernatants of Aspergillus fumigatus. J Infect Dis (1986) 1.05
Beta 1,4-oligoglucosides inhibit the binding of Aspergillus fumigatus conidia to human monocytes. J Infect Dis (1991) 1.05
Phagocytic and fungicidal activity of monocytes from patients with acquired immunodeficiency syndrome. J Infect Dis (1985) 1.04
Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis (1999) 1.02
Esophageal cryptococcosis in a patient with the hyperimmunoglobulin E-recurrent infection (Job's) syndrome. Gastroenterology (1984) 1.00
Identification of Cryptococcus neoformans in a routine clinical laboratory. Mycopathol Mycol Appl (1968) 1.00
Giant hairy nevus: preventable cause of amblyopia. J Pediatr Ophthalmol (1977) 0.99
Tolerance to cryptococcal polysaccharide in cured cryptococcosis patients: failure of antibody secretion in vitro. Clin Exp Immunol (1986) 0.97
Miconazole in cryptococcosis and systemic candidiasis: a word of caution. Ann Intern Med (1981) 0.97
Urease inhibition by EDTA in the two varieties of Cryptococcus neoformans. Infect Immun (1987) 0.96
Enhanced oxidative killing of azole-resistant Candida glabrata strains with ERG11 deletion. Antimicrob Agents Chemother (1996) 0.94
Cryptococcal skin test antigen: preparation variables and characterization. Infect Immun (1981) 0.94